Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer |
| |
Authors: | Jamie Wagner D.O. Judy C. Boughey M.D. Betsy Garrett P.A-C. Gildy Babiera M.D. Henry Kuerer M.D. Funda Meric-Bernstam M.D. Eva Singletary M.D. Kelly K. Hunt M.D. Lavinia P. Middleton M.D. Isabelle Bedrosian M.D. |
| |
Affiliation: | aDepartment of Surgical Oncology, The University of Texas; MD, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA |
| |
Abstract: | BackgroundOptimal surgical management of patients with invasive lobular carcinoma (ILC) who undergo neoadjuvant chemotherapy (NAC) is unknown. We evaluated optimal margin distance and local recurrence (LR) rates for these patients.MethodsNinety-three (30%) of 311 patients with ILC received NAC. We examined margin status, residual disease after re-excision, and clinical outcomes.ResultsMargin positivity rates after the final operative procedure were similar between the NAC and surgery-first group (P > .05). The proportion of patients, stratified by margin status, who were taken back for re-excision was not different between the 2 groups, and, similarly, there were no differences in frequency of residual disease (all P > .05). At a median follow-up of 3.1 years, 1 patient in the NAC group and 2 in the surgery-first group developed LR (P = 1.0).ConclusionsPatients with ILC who have undergone NAC and have margins >1 mm have a low probability of residual disease and LR. |
| |
Keywords: | Breast Lobular cancer Margins Neoadjuvant chemotherapy Local recurrence |
本文献已被 ScienceDirect 等数据库收录! |
|